Last checked at 
Hutchmed (China) Ltd - pharmaceutical company based in Hong-Kong - Says the European Medicines Agency has passed its marketing authorization application for surufatinib, a treatment for pancreatic and extra-pancreatic neuroendocrine tumours. Adds the agency's validation confirms that the submission is ready for formal review.
Notes that surufatinib is a novel oral treatment that selectively inhibits the tyrosine kinase activity to promote the body's immune response against tumour cells. Says submission to the European agency follows the conclusion of positive phase three studies of the drug in relevant neuroendocrine tumour patients in China.
Hutchmed International Corp Managing director and Chief Medical Officer Marek Kania, says: "Hutchmed's novel oncology pipeline is making important progress globally...With its launch earlier this year in China, surufatinib has given [neuroendocrine tumour] patients an important new therapeutic option and we now hope to soon be able to bring this important treatment to patients across the US and Europe."
Current stock price: 571.00 pence, up 5.0% on Friday morning
Year-to-date change: up 24%
By Scarlett Butler; scarlettbutler@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
